Esperion Presents Results from CLEAR Outcomes Primary : vima

– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary...

Related Keywords

Melbourne , Victoria , Australia , Monash , South Australia , United States , American , Stephen Nicholls , Tiffany Aldrich , Joanne Foody , Alexis Callahan , Sheldon Koenig , Twitter , Exchange Commission , Monash University , Journal Of The American Medical Association , American Diabetes Association , American Medical Association , Primary Prevention , Cardiovascular Events , Statin Intolerant Patients , Victorian Heart Hospital , Anne Foody , Chief Medical Officer , Primary Prevention Analysis , Acid Effects , High Sensitivityc Reactive Protein , Prescribing Information , Contact Information , Nasdaq Espr , Esperion Therapeutics , Nc ,